Hematologic Malignancy
B-Cell Neoplasm
CI-CAN-00000470Explore in graph →
HematologicNon-malignant2,097 active trials46 approved drugs301 evidence items
- NCIt
- C27907
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00000470Explore in graph →
Clinical trials
7,499 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05495464 | A Pilot "Window-3" Study of Acalabrutinib Plus Rituximab Followed by Brexucabtagene Autoleucel Therapy in Patients With Previously Untreated High-risk Mantle Cell Lymphoma | active not recruiting | Early Phase 1 | 22 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 12, 2026 | clinicaltrials |
| NCT02603887 | Pembrolizumab in Treating Patients With Intermediate or High-Risk Smoldering Multiple Myeloma | active not recruiting | Early Phase 1 | 20 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 17, 2026 |
| clinicaltrials |
| NCT04161248 | Phase I Master Protocol of Novel Combination Therapy for Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma | active not recruiting | Early Phase 1 | 40 | Canadian Cancer Trials GroupNETWORK | 1 | Jun 24, 2026 | clinicaltrials |
| NCT03680586 | Ultra Low-Dose Radiation Therapy in Treating Patients With Stage I-IV Stomach MALT Lymphoma | active not recruiting | Early Phase 1 | 25 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 15, 2026 | clinicaltrials |
| NCT01269593 | PET Imaging of Cancer Patients Using 124I-PUH71: A Pilot Study | active not recruiting | Early Phase 1 | 63 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jan 15, 2026 | clinicaltrials |
| NCT04370483 | Leflunomide for the Treatment of High-Risk Smoldering Multiple Myeloma | active not recruiting | Early Phase 1 | 1 | City of Hope Medical CenterOTHER | 1 | Jan 5, 2026 | clinicaltrials |
| NCT05560399 | A Study of Iberdomide (CC-220) in Combination With Elotuzumab and Dexamethasone for Relapsed/Refractory Multiple Myeloma(CC-220) | active not recruiting | Early Phase 1 | 7 | Icahn School of Medicine at Mount SinaiOTHER | 1 | Jan 2, 2026 | clinicaltrials |
| NCT05838131 | Study of CT071 Injection in RRMM or PPCL | active not recruiting | Early Phase 1 | 20 | Shanghai Changzheng HospitalOTHER | 1 | Jan 7, 2025 | clinicaltrials |
| NCT05302648 | To Evaluate the Safety and Efficacy of Human Derived Anti-BCMA CAR-T Injection for Subjects with R/R MM | active not recruiting | Early Phase 1 | 18 | Hrain Biotechnology Co., Ltd.INDUSTRY | 1 | Jan 3, 2025 | clinicaltrials |
Data updated 22 days agoSource updated Aug 12, 2026source: clinicaltrials